Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isofol Medical has recruited first patient in a single-center, open-label, extended feasibility Phase I/II LARS2 trial to evaluate Modufolin in conjunction with the anti-cancer drug Alimta, for the treatment of rectal cancer.
Subscribe to our email newsletter
Modufolin (6R-5,10-methylenetetrahydrofolate) is a novel folate-based drug developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment.
However, Eli Lilly’s Alimta is a folate analog metabolic inhibitor indicated for locally advanced or metastatic nonsquamous Non-Small Cell Lung Cancer and Mesothelioma.
In the Phase I/II trial, the company is planning to investigate Alimta (at 500mg/m2) with Modufolin (at 100, 50 or 10mg/m2) in 43 to 58 chemo-naive patients with newly diagnosed operable rectal cancer.
The study is being conducted in collaboration with the principal investigator Bengt Gustavsson and the Sahlgrenska University Hospital in Goteborg, Sweden.